working-with-us

Partner list

Overseas companies with whom we collaborate for business development in Japan are listed below. As some of our partners prefer to keep their Japanese business activities confidential, this is a partial list.

3B Pharma GmbH

Contract peptide drug discovery company with broad expertise spanning from hit identification to early clinical development. Proprietary programs under development in the nuclear medicine and oncology areas. Peptide expertise is also applied to the development of unique affinity purification reagents for industrial-scale bioprocess manufacturing processes.

Website: https://www.3b-pharma.com

Atuka Inc.

A leader in Parkinson’s Disease research, offering a comprehensive portfolio of non-human primate and other models to evaluate the effect of test compounds on Parkinson’s Disease. Offerings include proprietary models developed in-house as well as established traditional models. Atuka’s team of top-notch scientists has published over 300 papers in the Parkinson’s Disease research area.

Website: https://atuka.com

Avaden BioSciences Inc.

Provider of high quality human biomaterial samples with extensive levels of clinical annotation and active links to each patient’s Electronic Medical Record. This allows the selection of samples for highly specific biomarker strategies. Up to 350 data points per donor, including treatment details, response, outcome and survival.

Website: http://www.avadenbio.com

Crown Bioscience Inc.

A leading provider of cutting-edge disease models and analysis technologies for drug discovery and development. Offering a comprehensive Immune-Mediated Inflammatory Disease (IMID) assay portfolio which includes unique models to evaluate new drugs for polycystic kidney disease (PKD), cystic fibrosis and non-alcoholic steatohepatitis (NASH).

Website: https://www.crownbio.com

Epiontis GmbH

A world leader in epigenetic cell marker research. Focused on the immunology area, Epiontis develops proprietary epigenetic marker-based assays to detect and quantify specific immune cell types. This technology can be applied to clinical immunomonitoring as a superior alternative to FACS, as well as a robust cell identification methodology for cell-based therapies.

Website: https://www.epiontis.com

Glycomar Ltd.

Offering a unique technology platform for the discovery of novel glycomolecules with biological activity. Research is focused on marine organisms, ranging from invertebrates to microalgae. Active molecules are developed for applications in the pharmaceutical, consumer healthcare, nutraceutical and cosmetic areas.

Website: https://www.glycomar.com

bioExpert

Offering interim management, business development, and consulting for drug development and related services, with a special focus on neurodegenerative diseases. Eolas co-ordinates with bioExpert to market products and services of European companies with unique offerings in Japan, as well as selling Japan-based services in Europe and the US.

Website: https://www.bioexpert.biz

Jubilant Biosys Ltd.

Offering a wide range of contract research services for drug discovery, including structural biology, DMPK, early chemistry, in vivo efficacy models, computational chemistry, in vitro biology, toxicology and discovery informatics. Biosys has a highly successful track record of executing multi-disciplinary hit ID and lead optimization projects.

Website: https://www.jubilantbiosys.com

LifeSpan BioSciences, Inc. (LSBio)

A molecular pathology specialist maintaining a 2,500,000 specimen human tissue bank, and offering comprehensive immunohistochemistry (IHC) contract research services. This encompasses all aspects from study design through to pathology interpretation and reporting. LifeSpan has also developed a unique human tissue IHC database.

Website: https://www.lsbio.com

MAT BioTech B.V.

MAT Biotech offers a new human monocyte-based pyrogen testing kit offering numerous advantages over traditional pyrogen tests such as LAL and RPT. Fully compliant with European Pharmacopeia 2.6.30 requirements, the kit is intended for use in batch release testing of APIs and finished product.

Website: www.mat-biotech.com

Nilogen Oncosystems, LLC

A unique ex vivo tumor modeling technology based on fresh human cancer tissue. 3D-EXplore captures the full heterogeneity of individual human tumors and is regarded as the most clinically-relevant tumor microenvironment (TME) model available. The technology platform includes a broad portfolio of cutting-edge analysis technologies.

Website: https://nilogen.com

Optivia Biotechnology Inc.

Optivia’s proprietary technology has been used to develop the industry’s largest selection of functional human transporter assays in polarized mammalian cell lines. The assay portfolio contains many unique transporter models, including sophisticated multi-transporter models. Optivia recently became part of the BioIVT group.

Website: https://bioivt.com

Prodo Laboratories, Inc.

One of the world’s leading experts in human pancreatic islet research. Offering freshly isolated human islets and related materials, as well as islet-related contract research services to diabetes researchers. Prodo Labs has also developed a unique series of proprietary media for the transportation and culture of human pancreatic islets.

Website: https://prodolabs.com

Sirona Dx Inc.

Offering high-complexity single cell proteomics and genomics analysis services to support biopharma drug discovery and development programs. Sirona adopts new technologies at an early stage, benefiting clients via early access to cutting edge technologies. Studies are carried out in a CLIA accredited laboratory that supports pharmaceutical regulatory requirements.

Website: https://sironadx.com

StratiCELL SA

Providing pre-clinical testing services using unique in vitro and ex vivo skin models. With extensive expertise in skin tissue engineering and cell biology, StratiCELL helps its more than 250 dermo-cosmetic and pharmaceutical clients to obtain key biological data for objectives ranging from drug discovery to claim substantiation.

Website: https://straticell.com

Toxys B.V.

The developer of ToxTrackerTM, a unique mammalian stem cell-based technology to identify potential carcinogenic properties of novel compounds. ToxTrackerTM discriminates between genotoxicity arising from direct DNA damage, oxidative stress and protein damage, and can be particularly useful in an Adverse Outcome Pathway (AOP) approach.

Website: https://toxys.com